Grover Gary J, Marone Palma Ann, Koetzner Lee, Seto-Young Donna
Department of Pharmacology, Eurofins-Product Safety Laboratories, 2394 Highway 130, Dayton, NJ 08810, United States.
Int J Biochem Cell Biol. 2008;40(12):2698-701. doi: 10.1016/j.biocel.2008.06.013. Epub 2008 Jul 30.
The mitochondrial F1F0 ATP synthase is a critical enzyme that works by coupling the proton motive force generated by the electron transport chain via proton transfer through the F0 or proton-pore forming domain of this enzyme to release ATP from the catalytic F1 domain. This enzyme is regulated by calcium, ADP, and inorganic phosphate as well as increased transcription through several pathways. This enzyme is also an ATP hydrolase under ischemic conditions. This "inefficient" hydrolysis of ATP consumes 90% of ATP consumed during ischemia as shown with non-selective ATPase inhibitors oligomycin and Aurovertin B. A benzopyran analog, BMS-199264, selectively inhibits F1F0 ATP hydrolase activity with no effect on ATP synthase activity. BMS-199264 had no effect on ATP before ischemia, but reduced the decline in ATP during ischemia. Selective hydrolase inhibition seen with the small molecule BMS-199264 suggests a conformational change in the F1F0 ATPase enzyme when switching from synthase to hydrolase activity.
线粒体F1F0 ATP合酶是一种关键酶,其工作方式是通过质子通过该酶的F0或质子孔形成结构域转移,将电子传递链产生的质子动力与催化性F1结构域释放ATP相偶联。该酶受钙、ADP、无机磷酸盐调节,还可通过多种途径增加转录。在缺血条件下,该酶也是一种ATP水解酶。如使用非选择性ATP酶抑制剂寡霉素和金褐霉素B所示,这种“低效”的ATP水解消耗了缺血期间消耗的ATP的90%。一种苯并吡喃类似物BMS-199264选择性抑制F1F0 ATP水解酶活性,而对ATP合酶活性无影响。BMS-199264在缺血前对ATP无影响,但减少了缺血期间ATP的下降。小分子BMS-199264表现出的选择性水解酶抑制作用表明,当F1F0 ATP酶从合酶活性转变为水解酶活性时,其构象发生了变化。